The CANVAS Programme demonstrated that canagliflozin reduced major adverse cardiovascular events by 14% in patients with type 2 diabetes at high cardiovascular risk, but identified an approximately twofold increase in lower-extremity amputation risk, primarily at the toe or metatarsal level, requiring careful patient selection and monitoring.
Browsing: All
The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced cardiovascular death by 38% and heart failure hospitalisation by 35% in patients with type 2 diabetes and established cardiovascular disease — the first glucose-lowering agent to show a mortality benefit in a cardiovascular outcomes trial.
Summary: In patients with obesity and cardiovascular disease without diabetes (n=17,604) from the SELECT trial, once-weekly semaglutide 2.4 mg reduced…
Summary: In adults with obesity without type 2 diabetes (n=725) enrolled in the phase 3 SYNCHRONIZE-1 trial across 14 countries,…
Summary: In adults with obesity or overweight without type 2 diabetes from SURMOUNT-5, tirzepatide at maximum tolerated dose for 72…
Summary: In patients with biopsy-confirmed MASH and fibrosis stage F2-F3 (n=212), once-weekly pemvidutide (1.2 or 1.8 mg), a GLP-1/glucagon dual…
Summary: In adults with overweight or obesity following 7-day vancomycin treatment, 2′-fucosyllactose (2′-FL) supplementation for 8 weeks transiently improved gut…
Summary: In patients with type 2 diabetes inadequately controlled on metformin (n=60), adding sitagliptin 100 mg/day to metformin 2000 mg/day…
Summary: In patients with type 2 diabetes inadequately controlled on metformin and glyburide (n=32), sitagliptin add-on therapy for 6 months…
Summary: In adults with type 2 diabetes (n=40), Dibifree dietary phytomix (15 g/day) as add-on therapy significantly reduced HbA1c, fasting/postprandial…